Worldwide clinical trials take a major hit from pandemic, with endocrine targeted tests worst hit

Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit.

This is according to a new breakdown from Medidata (PDF), now owned by Dassault Systèmes, which aims to show by numbers how the COVID-19 pandemic has impacted global clinical trials.